Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Phase of Trial: Phase III
Latest Information Update: 11 Jun 2017
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Cervical cancer
- Focus Registrational; Therapeutic Use
- Acronyms AIM2CERV
- Sponsors Advaxis
- 02 Mar 2017 According to an Advaxis media release, update on this trial will be presented at Society of Gynecologic Oncology (SGO) Annual Meeting.
- 06 Feb 2017 According to an Advaxis media release, the first patient has been enrolled and dosed in this trial.
- 11 Oct 2016 Status changed from not yet recruiting to recruiting.